Venkatakrishnan, Karthik
EMD Serono, Inc.,
United States
2025 Rank: 103112
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 929 out of 157499 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 103112 | 93628 |
| Total Cites | 7060 | 8306 |
| H-index | 43 | 48 |
| Hm-index | 13 | 16 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 76 | 82 |
| Number of Single+First Authored Papers | 47 | 47 |
| Total Cites to Single+First Authored Papers | 2246 | 2652 |
| Number of Single+First+Last Authored Papers | 97 | 97 |
| Total Cites to Single+First+Last Authored Papers | 3090 | 3715 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 5498 | 5968 |
| Ratio of Total Citations to Distinct Citing Papers | 1.28 | 1.39 |
| Self-Citation Percentage |
15.00%
|
|
Venkatakrishnan, Karthik
EMD Serono, Inc.,
United States
2024 Rank: 101235
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 923 out of 148458 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 101235 | 94240 |
| Total Cites | 6589 | 7726 |
| H-index | 42 | 48 |
| Hm-index | 13 | 15 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 76 | 82 |
| Number of Single+First Authored Papers | 44 | 44 |
| Total Cites to Single+First Authored Papers | 2173 | 2546 |
| Number of Single+First+Last Authored Papers | 88 | 88 |
| Total Cites to Single+First+Last Authored Papers | 2879 | 3443 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 5111 | 5545 |
| Ratio of Total Citations to Distinct Citing Papers | 1.29 | 1.39 |
| Self-Citation Percentage |
14.72%
|
|
Venkatakrishnan, Karthik
EMD Serono Research and Development Institute, Inc.,
United States
2023 Rank: 97455
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 912 out of 140593 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 97455 | 93732 |
| Total Cites | 6232 | 7280 |
| H-index | 42 | 46 |
| Hm-index | 12 | 14 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 75 | 81 |
| Number of Single+First Authored Papers | 42 | 42 |
| Total Cites to Single+First Authored Papers | 2106 | 2462 |
| Number of Single+First+Last Authored Papers | 85 | 85 |
| Total Cites to Single+First+Last Authored Papers | 2732 | 3242 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4812 | 5219 |
| Ratio of Total Citations to Distinct Citing Papers | 1.30 | 1.39 |
| Self-Citation Percentage |
14.40%
|
|
Venkatakrishnan, Karthik
Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc.,
United States
2022 Rank: 95182
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 908 out of 134745 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 95182 | 94349 |
| Total Cites | 5789 | 6729 |
| H-index | 41 | 44 |
| Hm-index | 11 | 13 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 73 | 79 |
| Number of Single+First Authored Papers | 40 | 40 |
| Total Cites to Single+First Authored Papers | 2026 | 2353 |
| Number of Single+First+Last Authored Papers | 74 | 74 |
| Total Cites to Single+First+Last Authored Papers | 2556 | 3002 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4460 | 4830 |
| Ratio of Total Citations to Distinct Citing Papers | 1.30 | 1.39 |
| Self-Citation Percentage |
13.97%
|
|
Venkatakrishnan, Karthik
Takeda Oncology,
United States
2021 Rank: 94442
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 911 out of 131063 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 94442 | 92486 |
| Total Cites | 5565 | 6489 |
| H-index | 40 | 43 |
| Hm-index | 11 | 12 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 71 | 77 |
| Number of Single+First Authored Papers | 39 | 39 |
| Total Cites to Single+First Authored Papers | 1969 | 2291 |
| Number of Single+First+Last Authored Papers | 69 | 69 |
| Total Cites to Single+First+Last Authored Papers | 2463 | 2898 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4293 | 4653 |
| Ratio of Total Citations to Distinct Citing Papers | 1.30 | 1.39 |
| Self-Citation Percentage |
14.24%
|
|
Venkatakrishnan, Karthik
Takeda Pharmaceutical Company Limited,
United States
2020 Rank: 89944
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 826 out of 94611 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 89944 | 88725 |
| Total Cites | 5093 | 5959 |
| H-index | 39 | 42 |
| Hm-index | 10 | 12 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 71 | 77 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 1874 | 2180 |
| Number of Single+First+Last Authored Papers | 61 | 61 |
| Total Cites to Single+First+Last Authored Papers | 2279 | 2685 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3932 | 4265 |
| Ratio of Total Citations to Distinct Citing Papers | 1.30 | 1.40 |
| Self-Citation Percentage |
14.53%
|
|
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.